Skip to main content
Fig. 2 | Journal of Patient-Reported Outcomes

Fig. 2

From: A prospective study to validate the functional assessment of cancer therapy (FACT) for epidermal growth factor receptor inhibitor (EGFRI)-induced dermatologic toxicities FACT-EGFRI 18 questionnaire: SWOG S1013

Fig. 2

Criterion Validity For Each Symptom Based on Kappa Statistics Overall (Mean) and by Assessment Day. Criterion validity for the seven treatment toxicity categories most commonly associated with EGFRI toxicity. Criterion validity is based on agreement between the FACT-EGFRI 18 and the CTCAE scoring systems, and was assessed both overall and by assessment day. Moderate or better agreement is defined as Kappa coefficients of ≥0.41

Back to article page